Neel S Bhatt1,2, Ruta Brazauskas2,3, Heather R Tecca2, Jeanette Carreras2, Linda J Burns4, Rachel Phelan1, Rachel B Salit5,6, Karen L Syrjala5,7, Julie-An M Talano1, Bronwen E Shaw2. 1. Department of Pediatric Hematology/Oncology/Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin. 4. National Marrow Donor Program/Be The Match and CIBMTR, Minneapolis, Minnesota. 5. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 6. Department of Medicine, University of Washington, Seattle, Washington. 7. Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington.
Abstract
BACKGROUND: Data are scarce regarding employment outcomes of survivors of childhood allogeneic hematopoietic cell transplantation (alloHCT) and the factors that affect their employment status. METHODS: By using the Center for International Blood and Marrow Transplant Research database, the authors studied employment outcomes of ≥1-year survivors of childhood alloHCT who were age ≥18 years at their most recent assessment (year of transplantation, 1985-2010). Employment status was assessed at their attained ages (ages 18-22, 23-27, and 28-32 years) and according to transplantation center (TC) location (United States or International). A multivariable analysis assessing the factors that affected employed status (full-time/part-time work or student) was performed. RESULTS: Unemployment rates among 2844 survivors were persistently high at all attained ages (United States TCs: ages 18-22 [14%], 23-27 [15%], and 28-32 [13%] years; International TCs: ages 18-22 [56%], 23-27 [53%], and 28-32 [68%] years). The factors associated a with higher likelihood of employment included: older age at alloHCT (ages 5-9-years: hazard ratio [HR], 2.07; 95% confidence interval [CI], 1.65-2.6; ages 10-14 years: HR, 4.43; 95% CI, 3.58-5.47; ages 15-18-years: HR, 7.13; 95% CI, 5.72-8.88), myeloablative conditioning without total body irradiation (TBI) (HR, 1.56; 95% CI, 1.38-1.77), reduced-intensity conditioning with TBI (HR, 1.47; 95% CI, 1.19-1.8) or without TBI (HR, 2.51; 95% CI, 2.15-2.92), and US-based TC (HR, 1.84; 95% CI, 1.62-2.08). CONCLUSIONS: Young adult survivors of childhood alloHCT have high unemployment rates at all studied attained ages after HCT. Future efforts should be directed toward understanding the causes of unemployment their and relation to quality of life using patient-reported outcome measures.
BACKGROUND: Data are scarce regarding employment outcomes of survivors of childhood allogeneic hematopoietic cell transplantation (alloHCT) and the factors that affect their employment status. METHODS: By using the Center for International Blood and Marrow Transplant Research database, the authors studied employment outcomes of ≥1-year survivors of childhood alloHCT who were age ≥18 years at their most recent assessment (year of transplantation, 1985-2010). Employment status was assessed at their attained ages (ages 18-22, 23-27, and 28-32 years) and according to transplantation center (TC) location (United States or International). A multivariable analysis assessing the factors that affected employed status (full-time/part-time work or student) was performed. RESULTS: Unemployment rates among 2844 survivors were persistently high at all attained ages (United States TCs: ages 18-22 [14%], 23-27 [15%], and 28-32 [13%] years; International TCs: ages 18-22 [56%], 23-27 [53%], and 28-32 [68%] years). The factors associated a with higher likelihood of employment included: older age at alloHCT (ages 5-9-years: hazard ratio [HR], 2.07; 95% confidence interval [CI], 1.65-2.6; ages 10-14 years: HR, 4.43; 95% CI, 3.58-5.47; ages 15-18-years: HR, 7.13; 95% CI, 5.72-8.88), myeloablative conditioning without total body irradiation (TBI) (HR, 1.56; 95% CI, 1.38-1.77), reduced-intensity conditioning with TBI (HR, 1.47; 95% CI, 1.19-1.8) or without TBI (HR, 2.51; 95% CI, 2.15-2.92), and US-based TC (HR, 1.84; 95% CI, 1.62-2.08). CONCLUSIONS: Young adult survivors of childhood alloHCT have high unemployment rates at all studied attained ages after HCT. Future efforts should be directed toward understanding the causes of unemployment their and relation to quality of life using patient-reported outcome measures.
Authors: Jada G Hamilton; Lisa M Wu; Jane E Austin; Heiddis Valdimarsdottir; Katie Basmajian; Annamarie Vu; Scott D Rowley; Luis Isola; William H Redd; Christine Rini Journal: Psychooncology Date: 2012-05-18 Impact factor: 3.894
Authors: A Tichelli; S Gerull; A Holbro; A Buser; G Nair; M Medinger; D Heim; J P Halter; J R Passweg Journal: Bone Marrow Transplant Date: 2017-06-26 Impact factor: 5.483
Authors: Kirsten K Ness; Smita Bhatia; K Scott Baker; Liton Francisco; Andrea Carter; Stephen J Forman; Leslie L Robison; Joseph Rosenthal; James G Gurney Journal: Arch Pediatr Adolesc Med Date: 2005-08
Authors: Helena Harder; Jan J Cornelissen; Arthur R Van Gool; Hugo J Duivenvoorden; Wil M H Eijkenboom; Martin J van den Bent Journal: Cancer Date: 2002-07-01 Impact factor: 6.860
Authors: Eleshia J Morrison; Shawna L Ehlers; Carrie A Bronars; Christi A Patten; Tabetha A Brockman; James R Cerhan; William J Hogan; Shahrukh K Hashmi; Dennis A Gastineau Journal: Biol Blood Marrow Transplant Date: 2016-05-21 Impact factor: 5.742
Authors: Rajaram Nagarajan; Joseph P Neglia; Denis R Clohisy; Yutaka Yasui; Mark Greenberg; Melissa Hudson; Michael A Zevon; Jean M Tersak; Arthur Ablin; Leslie L Robison Journal: Cancer Date: 2003-05-15 Impact factor: 6.921
Authors: Clare Frobisher; Emma R Lancashire; Helen Jenkinson; David L Winter; Julie Kelly; Raoul C Reulen; Michael M Hawkins Journal: Int J Cancer Date: 2017-04-07 Impact factor: 7.396
Authors: J E Sanders; P A Hoffmeister; B E Storer; F R Appelbaum; R F Storb; K L Syrjala Journal: Bone Marrow Transplant Date: 2009-08-31 Impact factor: 5.483
Authors: Jenny W Y Pang; Debra L Friedman; John A Whitton; Marilyn Stovall; Ann C Mertens; Leslie L Robison; Noel S Weiss Journal: Pediatr Blood Cancer Date: 2008-01 Impact factor: 3.838
Authors: Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny Journal: Transplant Cell Ther Date: 2021-06-10
Authors: J Salchow; J Mann; B Koch; J von Grundherr; W Jensen; S Elmers; L A Straub; E Vettorazzi; G Escherich; S Rutkowski; S Dwinger; C Bergelt; M Sokalska-Duhme; S Bielack; G Calaminus; K Baust; C F Classen; C Rössig; J Faber; H Faller; I Hilgendorf; J Gebauer; T Langer; M Metzler; S Schuster; C Niemeyer; A Puzik; D Reinhardt; U Dirksen; A Sander; M Köhler; J K Habermann; C Bokemeyer; A Stein Journal: BMC Cancer Date: 2020-01-06 Impact factor: 4.430